Nov 13, 2013 by Dan CarrollJohnson & Johnson Investors Sweat, but the Dow Bounces BackThe Dow Jones pulls in the green as Johnson & Johnson's reported $4 billion-plus settlement over lawsuits sparks a dip.
Nov 12, 2013 by Dan CarrollThe Dow Jones Dives Alongside Johnson & JohnsonJohnson & Johnson investors step back from the stock's year-to-date gains on a day in the red for the markets
Nov 11, 2013 by Dan CarrollJohnson & Johnson and Merck Lead the Dow's Sluggish RiseJohnson & Johnson and Merck are two of big pharma's biggest stocks, but while the former's on the path to sustaining its long rise, the latter's taking a beating through patent losses and a weak pipeline
Nov 6, 2013 by Dan CarrollUnitedHealth Soars to Headline the Dow's 100-Point GainRival Humana's earnings surge helps UnitedHealth soar.
Nov 5, 2013 by Dan CarrollToday's 3 Best Stocks in the S&P 500Regeneron and Fossil make the most of earnings season, while ConAgra's stock turns around from a disastrous past three months.
Nov 5, 2013 by Dan CarrollBig Pharma Can't Capitalize on the Dow's Big ReboundThe Dow Jones claws back from hundred-point losses, but Pfizer and Merck remain mired in the red today.
Nov 4, 2013 by Dan CarrollMerck's Pipeline Hopes Lead the Dow's Bumpy Ride HigherMerck investors welcomed good news from the weekend, but Johnson & Johnson hit a rough stretch over a big legal payout.
Nov 2, 2013 by Dan Carroll3 Future Stars in Big Pharma's Best PipelineJohnson & Johnson is no stranger to developing strong pharmaceuticals for the long term, but which drugs should you keep an eye on that will keep this company's business on track in the future?
Nov 1, 2013 by Dan CarrollAre the DAX's German Auto Stocks Revving Up?Volkswagen has been a big winner for Germany's DAX this year, but can it and fellow German automakers BMW and Daimler ride the auto industry's rising tide?
Nov 1, 2013 by Dan CarrollThe PMI's Strong Showing Keeps the Dow Running HigherPfizer and Johnson & Johnson both shoot higher as the Dow's blue-chip stocks react favorably to the ISM's healthy PMI report
Nov 1, 2013 by Dan CarrollWill This Struggling Heart Device Maker Flatline?Edwards Lifesciences' stock has sunk in 2013, and worse news in on the way from rivals Medtronic and Boston Scientific. Can Edwards save its stock from disappointment?
Nov 1, 2013 by Dan Carroll1 Big Pharma Giant on the Verge of a TurnaroundSanofi's stock has performed well in 2013, but it hasn't kept up with industry leaders as sales have slipped. Will Sanofi's sales and shares pick up in the quarters to come?
Oct 31, 2013 by Dan Carroll3 Blockbuster Drugs Losing Patent Protection in 2013's Final MonthsEli Lilly, Amgen, and Merck KGaA all face big hits at the end of 2013 as generic competition revs for these three billion-dollar drugs.
Oct 31, 2013 by Dan CarrollJohnson & Johnson Helps the Slumbering Dow Climb HigherPfizer falls in the wake of strong earnings earlier this week, but it and rival Johnson & Johnson are battling for more than just day-to-day stock gains.
Oct 30, 2013 by Dan CarrollBig Pharma Slumps as the Dow Turns SouthThe Dow Jones loses momentum after its recent streak as Merck and Pfizer both fall to the bottom of the blue-chip index.
Oct 29, 2013 by Dan Carroll1 Booming Biotech That Didn't Disappoint This QuarterGilead Sciences' stock has surged in 2013, but after a strong third quarter, can this pick keep up its run?
Oct 29, 2013 by Dan CarrollPfizer's Earnings Beat Keeps the Dow on a Healthy HighThe Dow Jones soars behind Pfizer's rise, while Merck gains back some of what it lost yesterday.
Oct 28, 2013 by Dan CarrollMerck's Earnings Drop Weighs Down the Dow's AdvanceAfter Merck's profits nosedive by 35% for the quarter, Pfizer investors look ahead to the company's own quarterly report tomorrow
Oct 28, 2013 by Dan Carroll3 Takeaways You Need to Know From Merck's EarningsMerck's stock has been stuck in neutral over the past year, but will this company be able to evade the worst of the patent cliff's hits?
Oct 26, 2013 by Dan CarrollAlexion's Breakthrough Bounce Leads Biotech's Tepid Weekly GainsMedivation rockets higher behind strong clinical trial data, but Ariad Pharmaceuticals' jump comes with a big warning sign.
